Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
作者:Mariana Nacht、Lixin Qiao、Michael P. Sheets、Thia St. Martin、Matthew Labenski、Hormoz Mazdiyasni、Russell Karp、Zhendong Zhu、Prasoon Chaturvedi、Deepa Bhavsar、Deqiang Niu、William Westlin、Russell C. Petter、Aravind Prasad Medikonda、Juswinder Singh
DOI:10.1021/jm3008745
日期:2013.2.14
covalent inhibitor 3 (CNX-1351) was created that potently and specifically inhibits PI3Kα. We demonstrate, using mass spectrometry and X-ray crystallography, that the selective inhibitor covalently modifies PI3Kα on cysteine 862 (C862), an amino acid unique to the α isoform, and that PI3Kβ, -γ, and -δ are not covalently modified. 3 is able to potently (EC50 < 100 nM) and specifically inhibit signaling
PI3Kα已被鉴定为人类肿瘤中的致癌基因。通过使用合理的药物设计,可以有效而特异性地抑制PI3Kα的靶向共价抑制剂3(CNX-1351)被创建。我们使用质谱和X射线晶体学证明,选择性抑制剂共价修饰半胱氨酸862(C862)上的PI3Kα(一种仅对α亚型的氨基酸),并且PI3Kβ,-γ和-δ没有被共价修饰。图3的细胞能够有效地(EC 50<100nM)并且特异性地抑制PI3Kα依赖性癌细胞系中的信号传导,并且这导致有效的抗增殖作用(GI 50<100nM)。共价探针,8(CNX-1220)与PI3Kα选择性结合,用于研究3在体内对PI3Kα的占据持续时间。这是PI3Kα选择性抑制剂的首次报道,这些数据证明了选择性靶向PI3Kα的生物学影响。